Pirfenidone (trade names include Pirfenex, Esbriet, Etuary, Pirespa, Pulmofib) is an immunosuppressant medication from antineoplastic and immunomodulating agents pharmacological group. This medicine is used for the treatment of mild-to-moderate idiopathic pulmonary fibrosis, chronic liver fibrosis. In topical forms it is indicated for abnormal wound healing processes, skin ulcers, scars and fibrotic tissue. Pirfenidone works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
How and where to order Pirfenidone (Pirfenex) 200 mg tablets online on The Centre for Integral Economics:
|Prices:||from $0.70 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||200 mg tablets
|Quantity:||90, 180, 270, 360 pills
|Type:||Pirfenidone brand, Pirfenex brand and generics
|Payment:||Visa, MasterCard, AmEx, Discover
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Dimethyl Fumarate (DMF)
Pharmacological and medical categories:
Medicines for the therapy of idiopathic pulmonary fibrosis
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AX - Other immunosuppressants
L04AX05 - Pirfenidone
Other interstitial pulmonary diseases - J84
Pulmonary fibrosis, unspecified - J84.10
Idiopathic pulmonary fibrosis - J84.112
Fibrosis and cirrhosis of liver - K74
Other disorders of skin and subcutaneous tissue, not elsewhere classified - L98
Indications and usage:
Esbriet (Pirfenidone) is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Dosage and administration:
Take Pirfenidone with food.
Recommended dosage: 801 mg three times daily (2403 mg/day).
Upon initiation of treatment, titrateto the full dosage of 2403 mg/day over a 14-day period.
Consider temporary dosage reduction, treatment interruption, or discontinuation for management of adverse reactions.
Prior to treatment, conduct liver function tests.
Dosage forms and strengths:
Esbriet (Pirfenidone) capsules 267 mg, tablets 267 mg and 801 mg.
There is limited clinical experience with overdosage by Pirfenidone. Multiple dosages of Esbriet up to amaximum tolerated dose of 4005 mg per day were administered as five 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation.
In the event of a suspected overdosage, appropriate supportive medical care should be provided, including monitoring of vital signs and observation of the clinical status of the patient.
Warnings and precautions:
Elevated liver enzymesand drug-induced liver injury: ALT, AST, and bilirubin elevations have occurred with Esbriet including cases of drug-induced liver injury. In the postmarketing setting, non-serious and serious cases of drug-induced liverinjury, including severe liver injury with fatal outcomes, have been reported. Monitor ALT, AST, and bilirubin before and during treatment. Temporary dosage reductions or discontinuations may be required.
Photosensitivity and rash: photosensitivity and rash have been noted with Pirfenidone (Esbriet). Avoid exposure to sunlight and sunlamps. Wear sunscreen and protective clothing daily. Temporary dosage reductions or discontinuations may be required.
Gastrointestinal disorders: nausea, vomiting, diarrhea, dyspepsia, gastro-esophageal reflux disease, and abdominal painhave occurred with Pirfenidone. Temporary dosage reductions or discontinuations may be required.
Side effects, adverse reactions:
The most common adverse reactions ( >= 10%) of Pirfenidone are nausea, rash, upper respiratory tract infection, abdominal pain, diarrhea, headache, fatigue, dyspepsia, vomiting, dizziness, anorexia, sinusitis, insomnia, weight decreased, gastro-esophageal reflux disease, and arthralgia.
To report suspected adverse reactions, contact Genentech Inc. or your local FDA.
Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic exposure of Pirfenidone and may alter the adverse reaction profile of Esbriet. Discontinue fluvoxamine prior to administration of this drug or reduce to 267 mg three times a day. Consider dosage reduction with use of ciprofloxacin.
Use in specific populations:
Hepatic impairment: monitor for adverse reactions and consider dosagemodification or discontinuation of Esbriet as needed. This medication is not recommended for use in patients with severe hepatic impairment. Renal impairment: monitor for adverse reactions and consider dosage modification or discontinuation of Pirfenidone as needed. This medicine is not recommended for use in patients with end stage renal disease on dialysis.
Smokers: decreased exposure has been noted insmokers which may alter the efficacy profile of Esbriet (Pirfenidone) capsules and tablets.
B3 - Australia
C - United States (Risk cannot be ruled out)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Esbriet - Roche, AndersonBrecon Pharmaceuticals, Catalent, Genentech, Haemato Pharm, Intermune
Etuary - GNI Group
Fibridoner - DOSA Laboratorio
Mirfendo - MBA Pharmaceuticals
Misofagan - Tuteur Laboratorio
Oxitinol - LKM Laboratorio
Performa - Bago Laboratorios
Pirespa - Shionogi
Pirfect - Nobel Ilac
Pirfedo - Care Formulation Labs
Pirfefor - Fortune Healthcare
Pirfeheal - Healing Pharma
Pirfenex - Cipla
Pirfenidone - Lexicare Pharma
Pulmofib - MSN Laboratories
Here is a list of popular medications containing pirfenidone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Capsules; Oral; Pirfenidone 267 mgTablets; Oral; Pirfenidone 267 mgTablets; Oral; Pirfenidone 801 mg
||Tablets; Oral; Pirfenidone 200 mg
||Tablets, Film-Coated; Oral; Pirfenidone 200 mgTablets, Film-Coated; Oral; Pirfenidone 400 mg
Pirfenidone main article on Wikipedia: https://en.wikipedia.org/wiki/Pirfenidone
Pirfenidone compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Pirfenidone
Pirfenidone on DrugBank: https://go.drugbank.com/drugs/DB04951
Pirfenidone FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a615008.html
Esbriet (Pirfenidone) capsules 267 mg drug label information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Pirfenidone for sale on Pharma Doctor: https://pharma-doctor.com/pirfenidone.html
Pirfenidone international drug names on Drugs.com: https://www.drugs.com/international/pirfenidone.html
Esbriet (Pirfenidone) capsules 267 mg for oral use official prescribing information and medication guide from the U.S. FDA (revised 10/2014): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Esbriet (Pirfenidone) capsules 267 mg, tablets 267 mg and 801 mg prescribing and patient information from Genentech, Inc. (revised 07/2019): https://www.gene.com/download/pdf/esbriet_prescribing.pdf
Esbriet (Pirfenidone) hard capsules 267 mg package information leaflet from Medicines.org.uk (revised 11/2020): https://www.medicines.org.uk/emc/files/pil.3705.pdf
Esbriet (Pirfenidone) tablets official website for U.S. healthcare professionals: https://www.esbriethcp.com/
Esbriet (Pirfenidone) tablets official website for patients and caregivers: https://www.esbriet.com/
Pirfenex (Pirfenidone) film-coated tablets 200 mg and 400 mg prescribing information from Cipla (revised 01/2020): https://www.ciplamed.com/content/pirfenex-tablets
Revised: January 2021
Home | About Us | Projects | Services | News & Media | Support
Copyright © Centre for Integral Economics